Status:
COMPLETED
Case-Control Study of Inflammatory Breast Cancer in North Africa
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Diabetes
Eligibility:
FEMALE
18-100 years
Brief Summary
Background: * Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer. * Three characteristics of IBC tumors their rapid progression, their ext...
Detailed Description
Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer characterized by diffuse erythema and edema/peau d orange of the breast. The proposed ca...
Eligibility Criteria
Inclusion
- The case-control study will be restricted to women at least 18 years of age. IBC cases will be defined as having any clinical signs of redness, and either edema or peau d' orange characteristic of IBC or evidence of tumor emboli in the dermal lymphatics (at the center in Rabat).
- Cases with extensive ulceration of the breast or with breast carcinoma 'en cuirasse' will be excluded from the study, even if erythema is present.
- Women with a previous diagnosis of breast cancer will be excluded.
- All cancers will be pathologically confirmed with evidence of tumor in either the breast parenchyma or dermal lymphatics based on the diagnostic biopsy.
- Cases newly diagnosed and/or treated at study hospitals will be included.
Exclusion
Key Trial Info
Start Date :
November 17 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2018
Estimated Enrollment :
815 Patients enrolled
Trial Details
Trial ID
NCT00793390
Start Date
November 17 2008
End Date
September 30 2018
Last Update
December 24 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute-Cairo
Cairo, Egypt
2
Gharbia Cancer Society
Gharbia, Egypt
3
Tanta Cancer Center
Tanta, Egypt
4
Ibn Rochd Oncology Center
Casablanca, Morocco